Inês Martins, PhD
May 15, 2017
A pre-clinical study to evaluate the therapeutic potential of a bioelectronic platform in preventing and reducing inflammation in non-alcoholic steatohepatitis (NASH) is beginning, its developer, Endonovo Therapeutics, announced. This is the first of multiple planned studies assessing the Immunotronics platform in inflammatory liver diseases, it said.
“We are delighted [to be] kick-starting our liver disease pipeline targeting large and unmet clinical needs, particularly in fatty liver disease,” Alan Collier, Endonovo CEO, said in a press release.
The Immunotronics platform is a non-invasive, non-implantable bioelectronics device that delivers a patented electromagnetic field, through coils or antennas, to a designated area of the body as a non-drug therapy.
It uses the naturally occurring electromagnetic pulses that control a variety of activities in our bodies, activating specific electrical field pathways with anti-inflammatory properties in tissues and organs.
Unlike other magnetic pulse devices, the Immonotronics platform uses time-varying electromagnetic field technology, producing waves designed to be intense enough to stimulate an immune response and able to penetrate deep within tissues.